Abstract
Medulloblastomas (MB) are highly malignant but potentially curable, embryonal brain tumors. MB develop in the cerebellum but have a high propensity to metastasize to the subarachnoid space. As of WHO 2021, MB are either molecularly defined, including the WNT-activated, SHH-mutant and TP53-wildtype, SHH-mutant, and TP53-mutant, and non-WNT/non-SHH subtypes; or histologically defined. While MB are common brain tumors in children, they account for less than 1% of adult brain tumors. This chapter will focus on adult MB, however much of the evidence for treatment is extrapolated from childhood MB.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Waszak SM, Northcott PA, Buchhalter I, et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018;19:785–98.
Chang CH, Housepian EM, Herbert C Jr. An operative staging system and a megavoltage radiotherapeutic technique for cerebellar medulloblastomas. Radiology. 1969;93:1351–9.
Zhao F, Ohgaki H, Xu L, et al. Molecular subgroups of adult medulloblastoma: a long-term single-institution study. Neuro Oncol. 2016;18:982–90.
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.
Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012;123:473–84.
Remke M, Hielscher T, Northcott PA, et al. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol. 2011;29:2717–23.
Franceschi E, Hofer S, Brandes AA, et al. EANO–EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. Lancet Oncol. 2019;20:e715–28.
De B, Beal K, De Braganca KC, et al. Long-term outcomes of adult medulloblastoma patients treated with radiotherapy. J Neurooncol. 2018;136:95–104.
Brown AP, Barney CL, Grosshans DR, et al. Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. Int J Radiat Oncol Biol Phys. 2013;86:277–84.
Beier D, Proescholdt M, Reinert C, et al. Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). Neuro Oncol. 2018;20:400–10.
Kunschner LJ, Kuttesch J, Hess K, Yung WK. Survival and recurrence factors in adult medulloblastoma: the M.D. Anderson Cancer Center experience from 1978 to 1998. Neuro Oncol. 2001(3):167–73.
Brandes AA, Franceschi E, Tosoni A, Blatt V, Ermani M. Long-term results of a prospective study on the treatment of medulloblastoma in adults. Cancer. 2007;110:2035–41.
Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol. 2019;21:v1–v100.
Li Q, Dai Z, Cao Y, Wang L. Comparing children and adults with medulloblastoma: a SEER based analysis. Oncotarget. 2018;9:30189–98.
Brandes AA, Bartolotti M, Marucci G, et al. New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology. Crit Rev Oncol Hematol. 2015;94:348–59.
Gill P, Litzow M, Buckner J, et al. High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system. Cancer. 2008;112:1805–11.
Li Y, Song Q, Day BW. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systematic review and meta-analysis. Acta Neuropathol Commun. 2019;7:123.
Harrison RA, Kesler SR, Johnson JM, Penas-Prado M, Sullaway CM, Wefel JS. Neurocognitive dysfunction in adult cerebellar medulloblastoma. Psychooncology. 2019;28:131–8.
Kahalley LS, Peterson R, Ris MD, et al. Superior intellectual outcomes after proton radiotherapy compared with photon radiotherapy for pediatric medulloblastoma. J Clin Oncol. 2020;38:454–61.
Packer RJ, Zhou T, Holmes E, Vezina G, Gajjar A. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children’s Oncology Group trial A9961. Neuro Oncol. 2013;15:97–103.
Roongpiboonsopit D, Kuijf HJ, Charidimou A, et al. Evolution of cerebral microbleeds after cranial irradiation in medulloblastoma patients. Neurology. 2017;88:789–96.
Franceschi E, Bartolotti M, Paccapelo A, et al. Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients? J Neurooncol. 2016;128:235–40.
Moots PL, O’Neill A, Londer H, et al. Preradiation chemotherapy for adult high-risk medulloblastoma: a trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol. 2018;41:588–94.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
McGranahan, T., Partap, S. (2023). Adult Medulloblastoma. In: Mohile, N.A., Thomas, A.A. (eds) Brain Tumors. Springer, Cham. https://doi.org/10.1007/978-3-031-41413-8_7
Download citation
DOI: https://doi.org/10.1007/978-3-031-41413-8_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-41412-1
Online ISBN: 978-3-031-41413-8
eBook Packages: MedicineMedicine (R0)